AZ Delta

Running trials

• Not yet recruiting

  Evaluating the Safety and Performance of the Eight Medical Hyperthermia System IV 1.0 for HIVEC in NMIBC.

  NCT07758881· Source

• Recruiting

  Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  NCT07648264· Phase 3· Source

• Not yet recruiting

  A Study of Barrett's Esophagus Patients: Optimization of a Risk Model to Better Predict the Development of Cancer Recurrence and the Effect of Risk Profile Disclosure on Patient Quality of Life and Fear of Cancer

  NCT07455422· Source

• Recruiting

  Study of INCA036978 in Participants With Myeloproliferative Neoplasms

  NCT07441694· Phase 1· Source

• Recruiting

  A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  NCT07218341· Phase 4· Source

• Recruiting

  Effect of IMT in Patients After Acute Exacerbations of COPD

  NCT07213128· Source

• Recruiting

  Optimized Expansion of the Implanted Transcatheter Aortic Valve

  NCT07042529· Source

• Recruiting

  A Study of Barrett's Esophagus Patients to Investigate Quality of Life and Fear of Cancer, and Optimize a Risk Model Based on Biomarkers and New Technologies to Better Predict the Development of Cancer

  NCT06523374· Source

• Recruiting

  Achieving a Better Outcome Through Limiting the Glioblastoma Clinical Target Volume

  NCT06719440· Source

• Recruiting

  Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

  NCT06801834· Phase 3· Source

• Recruiting

  Improving the Use of Immunotherapy to Treat Liver Cancer

  NCT07623265· Source

• Active, not recruiting

  A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

  NCT06686615· Source

• Recruiting

  Study on the Clinical Efficacy of Teclistamab and Talquetamab

  NCT06477783· Source

• Recruiting

  Perioperative SDD to Prevent Infectious Complications After Esophagectomy

  NCT05865743· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

  NCT06388564· Phase 2· Source

• Recruiting

  Stereotactic Body Radiation Therapy for Inoperable Non-metastasized Pancreatic Adenocarcinoma

  NCT06691425· Source

• Recruiting

  The RECLAIM Study.

  NCT06450444· Source

• Recruiting

  Colchicine in Belgium in Patients With Coronary Artery Disease After Percutaneous Coronary Intervention

  NCT06095765· Phase 3· Source

• Recruiting

  A Phase 1/2 study of Enzomenib (DSP-5336) in Patients with Acute leukemia

  2022-502741-10-00· Phase 1/2· Source

• Recruiting

  Physical Activity Coaching After Surgery for Patients With Resectable Non-small Cell Lung Cancer

  NCT06057766· Source

• Recruiting

  A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

  NCT06149286· Phase 3· Source

• Active, not recruiting

  REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

  NCT05973773· Phase 3· Source

• Recruiting

  Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 Trial

  2022-501551-90-00· Phase 2/3· Source

• Recruiting

  Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers

  NCT06282588· Phase 2/3· Source

• Recruiting

  A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT05730036· Phase 3· Source

• Recruiting

  Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

  NCT05855200· Phase 3· Source

• Active, not recruiting

  Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease

  NCT05910528· Phase 2· Source

• Active, not recruiting

  A Study of Zigakibart in Adults With IgA Nephropathy

  NCT05852938· Phase 3· Source

• Active, not recruiting

  Atacicept in Subjects With IgA Nephropathy

  NCT04716231· Phase 3· Source

• Recruiting

  A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

  NCT05878769· Phase 3· Source

• Recruiting

  Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer

  NCT06896890· Phase 1/2· Source

• Recruiting

  An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

  NCT05907057· Phase 3· Source

• Active, not recruiting

  First Evaluation of a Craniofacial Nerve Stimulation System in Chronic Migraine

  NCT05858801· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Source

• Recruiting

  Liquid Biopsies in Esophageal Cancer

  NCT05704530· Source

• Active, not recruiting

  Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

  NCT05445778· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

  NCT05578976· Phase 3· Source

• Active, not recruiting

  ABTECT - Maintenance

  NCT05535946· Phase 3· Source

• Recruiting

  What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?

  NCT04436978· Phase 4· Source

• Recruiting

  Met Non Small Cell Cancer Registry (MOMENT)

  NCT05376891· Source

• Recruiting

  Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy

  NCT05169593· Phase 4· Source

• Active, not recruiting

  Left Bundle Branch Area Pacing Using Conventional Stylet-driven Pacemaker Leads for Cardiac Resynchronization Therapy

  NCT05365568· Source

• Recruiting

  Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients

  NCT05491200· Phase 4· Source

• Recruiting

  Metastasis-directed Therapy for Oligorecurrent Prostate Cancer

  NCT05352178· Phase 3· Source

• Recruiting

  Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

  NCT04685616· Phase 3· Source

• Recruiting

  A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  NCT04988555· Phase 1/2· Source

• Recruiting

  The Stress-obesity Axis: a Metabolomics Approach Towards Personalized Nutrition in Adolescents

  NCT06391671· Source

• Recruiting

  First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

  NCT05099172· Phase 1/2· Source

• Recruiting

  Belgian Registry on Coronary Function Testing

  NCT06089031· Source

• Recruiting

  A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

  NCT04710576· Phase 2· Source

Showing 50 of 68.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers4 recruiting
• Coronary artery disease4 recruiting
• Gastric and oesophageal cancer4 recruiting
• Lung cancer3 recruiting
• Multiple myeloma3 recruiting
• Prostate cancer3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Acute myeloid leukaemia2 recruiting
• Atrial fibrillation2 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• COPD2 recruiting
• Myelodysplastic syndromes2 recruiting
• Bladder cancer1 recruiting
• Crohn's disease1 recruiting
• Glioblastoma1 recruiting
• Hodgkin lymphoma1 recruiting
• Liver and biliary tract cancer1 recruiting
• Migraine1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Obesity1 recruiting
• Pancreatic cancer1 recruiting
• Parkinson disease1 recruiting
• Stroke1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer

  NCT06595563· Phase 2· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

  NCT06066515· Phase 3· Source

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Source

• Active, not recruiting

  A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

  NCT05904886· Phase 3· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Vixarelimab Compared with Placebo in Patients with Idiopathic Pulmonary Fibrosis and in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

  2022-502828-42-00· Phase 2· Source

• Active, not recruiting

  Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

  NCT05740566· Phase 3· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Source

• Completed

  First-in-human phase I/IIa study investigating inhaled CIS-DPI as add-on treatment in Stage IV NSCLC patients

  2022-501183-17-00· Phase 1/2· Source

• Completed

  ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

  NCT05507216· Phase 3· Source

• Completed

  ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA

  NCT05992142· Phase 4· Source

• Terminated

  A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

  NCT05556616· Phase 1· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Source

• Active, not recruiting

  Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

  NCT05471843· Phase 1/2· Source

• Terminated

  The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

  NCT04985968· Phase 3· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05037929· Phase 2· Source

• Terminated

  A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

  NCT04809467· Phase 1/2· Source

• Completed

  A Study of Surgical Interventions in Fistulizing Conditions

  NCT04940611· Source

• Active, not recruiting

  Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).

  NCT04895722· Phase 2· Source

• Terminated

  To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

  NCT04551053· Phase 3· Source

• Terminated

  To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

  NCT04551066· Phase 3· Source

• Completed

  A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study with a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease

  2022-501188-42-00· Phase 2· Source

• Completed

  Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis

  NCT04607837· Phase 2· Source

• Completed

  Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation (POPular PAUSE TAVI)

  NCT04437303· Phase 4· Source

• Terminated

  Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis

  NCT04883840· Phase 2/3· Source

• Completed

  COronary and MICrocirculatory Measurements in Patients With Aortic Valve Stenosis.

  NCT04420325· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Source

• Active, not recruiting

  The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL

  NCT03463057· Phase 2· Source

• Active, not recruiting

  Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

  NCT03425643· Phase 3· Source

• Completed

  Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

  NCT02950051· Phase 3· Source

• Completed

  A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

  NCT02620046· Phase 3· Source

• Completed

  Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

  NCT01938248· Phase 4· Source